Nilotinib Stada Arzneimittel (Nilotinib)

Nilotinib blocks the BCR‑ABL tyrosine kinase by binding to its ATP‑binding pocket. This prevents downstream signaling that drives uncontrolled growth of leukemic cells, leading to cell‑cycle arrest and programmed cell death. It also retains activity against many BCR‑ABL mutations that cause resistance to older agents.

The specific dose of Nilotinib is determined by the prescribing clinician based on the patient’s disease stage, prior therapy, and individual tolerability. Dosing recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.

The safety of Nilotinib in pregnancy and lactation has not been established. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Compared with imatinib, the first‑generation BCR‑ABL inhibitor, Nilotinib offers higher potency and activity against several resistance‑conferring mutations. Clinical studies have shown faster and deeper molecular responses, though both agents share similar safety considerations such as cardiovascular monitoring. Choice of therapy depends on individual patient factors and prior treatment history.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity, which could compromise tablet integrity.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal or a light snack. The tablets should be swallowed with water and not crushed, chewed, or divided unless specifically instructed by the prescriber. Dosing times are typically spaced 12 hours apart to maintain steady plasma concentrations.

The most critical risks include cardiovascular events such as arterial occlusive disease, QT‑interval prolongation that can lead to serious arrhythmias, severe liver injury, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for cardiac symptoms, liver function abnormalities, and any signs of severe skin toxicity.

Nilotinib should be avoided in patients with a known hypersensitivity to the drug or any of its excipients, those with uncontrolled cardiovascular disease, significant QT prolongation, or severe hepatic impairment. It is also contraindicated in pregnant or breastfeeding women unless the potential benefit outweighs the risk, and in individuals taking strong CYP3A4 inhibitors or inducers without appropriate dose adjustments.